David A. Siegel Verve Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 36,700 shares of VERV stock, worth $179,096. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,700Holding current value
$179,096% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VERV
# of Institutions
170Shares Held
78.3MCall Options Held
125KPut Options Held
185K-
Alphabet Inc. Mountain View, CA12.3MShares$60.3 Million7.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.33MShares$30.9 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.04MShares$29.5 Million0.57% of portfolio
-
Black Rock Inc. New York, NY5.37MShares$26.2 Million0.0% of portfolio
-
State Street Corp Boston, MA5.1MShares$24.9 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $293M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...